Amyloid β accelerates phosphorylation of tau and neurofibrillary tangle formation in an amyloid precursor protein and tau double‐transgenic mouse model
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
In Alzheimer's disease, Aβ deposits are considered the initial cardinal events that induce tauopathy secondarily. However, the relationship between Aβ amyloidosis and tauopathy has not been determined in detail. We produced double transgenic mice, 2×TgTau+/–APP+/–, by mating Tg2576 mice that exhibit Aβ amyloidosis and TgTauP301L mice that show tauopathy, and statistically analyzed the effect of Aβ accumulation on tauopathy. There was no significant difference in theprogression of Aβ accumulation among 2×TgTau+/–APP+/– and 1×TgTau−/–APP+/–, and tau accumulation among 2×TgTau+/−APP+/− and 1×Tg Tau+/–APP−/–. The appearance rates of phosphorylated tau developing in neurons and processes were significantly accelerated in 2×TgTau+/–APP+/– mice compared with those in 1×TgTau+/–APP−/– mice at 23 months of age. Accumulation of phosphorylated and confomationally altered tau and GSK3β in neuronal processes was accelerated in the white matter in 2×TgTau+/–APP+/–. The level of phosphorylated tau in the sarkosyl‐insoluble fraction was increased in 2×TgTau+/–APP+/– brains compared with that in 1×TgTau+/–APP−/– brains. Thus, Aβ amyloid partially enhances tauopathy through accumulation of insoluble, phosphorylated, and conformationally changed tau in neuronal cytoplasm and processes in the late stage. © 2010 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 2×
“olfactory cortex (Lewis et al., 2001), investigations into mechanisms underlying Ab induced tauopathy have been facilitated.”
BackgroundInfluentialFormation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 4×
“Injection of Ab42 fibrils or brain Ab extracts into the brains of the tau transgenic mice models caused increases in the number of NFTs (Götz et al., 2001).”
BackgroundInfluentialHolmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416 · cited 1×
“However, follow-up of a phase I trial of immunization with Ab42 did not prevent clinical progression of dementia, tauopathy, or neuronal cell loss, even though it resulted in the clearance of amyloid plaques (Holmes et al., 2008).”
BackgroundHolcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., et al. (1998) · Nature Medicine · doi:10.1038/nm0198-097 · Cited by 1,386
The amyloid hypothesis for Alzheimer’s disease: A critical reappraisal
Hardy, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06181.x · Cited by 814 · cited 1×
“Soluble Ab oligomers are considered the cardinal molecules that adversely affect synaptic structures and plasticity (Hardy, 2009).”
BackgroundTau is essential to β-amyloid-induced neurotoxicity
Rapoport, M., Dawson, H. N., Binder, L. I., Vitek, M. P., & Ferreira, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092136199 · Cited by 807
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004) · Neuron · doi:10.1016/j.neuron.2004.07.003 · Cited by 780
Spires, T. L., Orne, J. D., SantaCruz, K., Pitstick, R., Carlson, G. A., Ashe, K. H., & Hyman, B. T. (2006) · The American Journal of Pathology · doi:10.2353/ajpath.2006.050840 · Cited by 401
Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease
Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507892200 · Cited by 379 · cited 2×
“Reduction of both soluble Ab and tau levels have been suggested as necessary to rescue cognitive impairment in 33Tg-AD model mice (Oddo et al., 2006a).”
Backgroundde Calignon, A., Spires-Jones, T. L., Pitstick, R., Carlson, G. A., & Hyman, B. T. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181a9fc66 · Cited by 81
Genetically Altering Aβ Distribution from the Brain to the Vasculature Ameliorates Tau Pathology
Oddo, S., Caccamo, A., Cheng, D., & LaFerla, F. M. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00194.x · Cited by 33 · cited 1×
“The somatodendritic tau accumulation is dependent on parenchymal Ab deposits (Oddo et al., 2009).”
Background
Cited by
Takeuchi, H., Iba, M., Inoue, H., Higuchi, M., Takao, K., Tsukita, K., Karatsu, Y., Iwamoto, Y., Miyakawa, T., Suhara, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021050 · Cited by 247
Enhanced tau aggregation in the presence of Amyloid β
Bennett, R. E., DeVos, S. L., Dujardin, S., Corjuc, B., Gor, R., Gonzalez, J., Roe, A. D., Frosch, M. P., Pitstick, R., Carlson, G. A., et al. (2017) · The American Journal of Pathology · doi:10.1016/j.ajpath.2017.03.011 · Cited by 245
Tau reduction in the presence of amyloid-β prevents tau pathology and neuronal death in vivo
DeVos, S. L., Corjuc, B. T., Commins, C., Dujardin, S., Bannon, R. N., Corjuc, D., Moore, B. D., Bennett, R. E., Jorfi, M., Gonzales, J. A., et al. (2018) · Brain · doi:10.1093/brain/awy117 · Cited by 106
Héraud, C., Goufak, D., Ando, K., Leroy, K., Suain, V., Yilmaz, Z., De Decker, R., Authelet, M., Laporte, V., Octave, J.-N., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.010 · Cited by 80
“The enhancement of tauopathy by Aß accumulation in APP/tau models has been described in some models as slow, developing with aging, and relatively modest (Paulson et al., 2008; Perez et al., 2005; Seino et al., 2010; Terwel et al., 2008).”
BackgroundKanno, T., Tsuchiya, A., & Nishizaki, T. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.08.034 · Cited by 76
Metadata
- Authors
- Seino, Y., Kawarabayashi, T., Wakasaya, Y., Watanabe, M., Takamura, A., Yamamoto‐Watanabe, Y., Kurata, T., Abe, K., Ikeda, M., Westaway, D., Murakami, T., Hyslop, P. S. G., Matsubara, E., & Shoji, M.
- Venue
- Journal of Neuroscience Research
- Publisher
- Wiley
- Published
- 2010-10-08
- Volume
- 88
- Issue
- 16
- Pages
- 3547-3554
- ISSN
- 0360-4012 (ISSN-L)
- 1097-4547
- OpenAlex
- W2030813189
- Cited by
- 31
- References
- 11
- FWCI
- 0.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.